Regulation of intestinal LDLR by the LXR-IDOL axis

Nienke M van Loon; Suzanne A E van Wouw; Roelof Ottenhoff; Jessica K Nelson; Jenina Kingma; Saskia Scheij; Martina Moeton; Noam Zelcer

doi:10.1016/j.atherosclerosis.2020.10.898

Regulation of intestinal LDLR by the LXR-IDOL axis

Atherosclerosis. 2020 Dec:315:1-9. doi: 10.1016/j.atherosclerosis.2020.10.898. Epub 2020 Nov 9.

Authors

Nienke M van Loon¹, Suzanne A E van Wouw¹, Roelof Ottenhoff¹, Jessica K Nelson¹, Jenina Kingma¹, Saskia Scheij¹, Martina Moeton¹, Noam Zelcer²

Affiliations

¹ Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Cardiovascular Sciences and Gastroenterology and Metabolism, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, the Netherlands.
² Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Cardiovascular Sciences and Gastroenterology and Metabolism, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, the Netherlands. Electronic address: n.zelcer@amsterdamumc.nl.

PMID: 33190106
DOI: 10.1016/j.atherosclerosis.2020.10.898

Abstract

Background and aims: Cholesterol metabolism is tightly regulated by transcriptional and post-transcriptional mechanisms. Accordingly, dysregulation of cholesterol metabolism is a major risk factor for the development of coronary artery disease and associated complications. In recent years, it has become apparent that next to the liver, the intestine plays a key role in systemic cholesterol metabolism by governing cholesterol absorption, secretion, and incorporation into lipoprotein particles. We have previously demonstrated that the Liver X receptor (LXR)-regulated E3 ubiquitin ligase inducible degrader of LDLR (IDOL) is a regulator of cholesterol uptake owing to its ability to promote the ubiquitylation of the low-density lipoprotein receptor (LDLR). However, whether the LXR-IDOL-LDLR axis regulates the LDLR in the intestine and whether this influences intestinal cholesterol homeostasis is not known.

Methods: In this study, we evaluated the role of the LXR-IDOL-LDLR axis in enterocyte cell models and in primary enterocytes isolated from Idol^(-/-) and wild type mice. Furthermore, we studied the regulation of intestinal LDLR in Idol^(-/-) and in wild type mice treated with the LXR agonist GW3965. Finally, we assessed ezetimibe-induced trans-intestinal cholesterol efflux in Idol^(-/-) mice.

Results: We show that in a wide range of intestinal cell lines LXR activation decreases LDLR protein abundance, cell surface occupancy, and LDL uptake in an IDOL-dependent manner. Similarly, we find that pharmacological dosing of C57BL6/N mice with the LXR agonist GW3965 increases Idol expression across the intestine with a concomitant reduction in Ldlr protein. Conversely, primary enterocytes isolated from Idol^(-/-) mice have elevated Ldlr. To test whether these changes contribute to trans-intestinal cholesterol efflux, we measured fecal cholesterol in mice following ezetimibe dosing, but found no differences between Idol^(-/-) and control mice in this setting.

Conclusions: In conclusion, our study establishes that the LXR-IDOL-LDLR axis is active in the intestine and is part of the molecular circuitry that maintains cholesterol homeostasis in enterocytes.

Keywords: Cholesterol metabolism; IDOL; LDLR; LXR; TICE.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Intestines
Liver X Receptors
Mice
Orphan Nuclear Receptors* / genetics
Receptors, LDL* / genetics
Receptors, LDL* / metabolism
Ubiquitin-Protein Ligases / genetics
Ubiquitination

Substances

Liver X Receptors
Orphan Nuclear Receptors
Receptors, LDL
Ubiquitin-Protein Ligases